FDA Brief

Warning letters Drugs

FDA warning letter to

JB Exchange Inc./Justified Laboratories

High riskIssued Aug 4, 2022Posted Aug 9, 2022Center for Drug Evaluation and Research | CDER

JB Exchange/Justified Laboratories sold unapproved skin tag and mole removal serums online, FDA says.

What happened

In August 2022, FDA reviewed www.justifiedlaboratories.com and found it took orders for Skincell Advanced and Skincell. FDA said website claims showed the products were intended to remove skin tags and moles, making them unapproved new drugs. FDA found this through a website review, not an inspection.

What FDA found

  1. The products are unapproved new drugs because the website claims they treat or remove moles and skin tags.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. The products are new drugs not generally recognized as safe and effective for their claimed uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. No FDA-approved applications are in effect for the products, so selling them violates the law.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  4. The website claims establish that the products are intended for use as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  5. FDA warns that no OTC drugs can legally be sold for mole or skin tag removal and that self-treatment can delay cancer diagnosis and cause injury or scarring.

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, including steps to prevent recurrence and related documentation. If corrective actions cannot be completed, the company must state the reason for delay and the time within which it will complete them.

Who should pay attention

  • online sellers of skin tag or mole removal products
  • brands making drug-like claims for cosmetics or serums
  • e-commerce platforms hosting such product pages

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk